{
  "trial_name": "PDS310-Original",
  "description": "Panitumumab + BSC vs BSC alone in RAS wild-type metastatic colorectal cancer",
  "phase": "3",
  "n_patients": 300,
  "allocation_ratio": [
    1.0,
    1.0
  ],
  "treatment_arms": [
    {
      "name": "Panitumumab + BSC",
      "description": "Panitumumab 6 mg/kg IV Q2W + best supportive care",
      "response_rate_modifier": 1.5,
      "ttr_modifier": 1.0,
      "os_hr": 0.88,
      "pfs_hr": 0.54,
      "is_control": false
    },
    {
      "name": "BSC",
      "description": "Best supportive care alone",
      "response_rate_modifier": 1.0,
      "ttr_modifier": 1.0,
      "os_hr": 1.0,
      "pfs_hr": 1.0,
      "is_control": true
    }
  ],
  "eligibility": {
    "min_age": 18,
    "max_age": null,
    "required_ecog": [
      0,
      1,
      2
    ],
    "ras_status": [
      "WILD-TYPE"
    ],
    "min_weight": null,
    "max_weight": null,
    "required_sex": null,
    "exclude_prior_egfr": false
  },
  "endpoints": [
    {
      "name": "Overall Survival",
      "endpoint_type": "primary",
      "metric": "os",
      "test_type": "survival",
      "alpha": 0.05,
      "power": 0.8,
      "target_hr": 0.88,
      "target_difference": null
    },
    {
      "name": "Progression-Free Survival",
      "endpoint_type": "secondary",
      "metric": "pfs",
      "test_type": "survival",
      "alpha": 0.05,
      "power": 0.8,
      "target_hr": 0.54,
      "target_difference": null
    },
    {
      "name": "Overall Response Rate",
      "endpoint_type": "secondary",
      "metric": "response_rate",
      "test_type": "proportion",
      "alpha": 0.05,
      "power": 0.8,
      "target_hr": null,
      "target_difference": null
    }
  ],
  "stratification_factors": [
    "baseline_ecog",
    "num_metastatic_sites"
  ],
  "random_seed": 42,
  "max_followup_days": 730,
  "arm_sizes": {
    "Panitumumab + BSC": 150,
    "BSC": 150
  }
}